1h Free Analyst Time
According to the recently published report 'Nicotinamide Phosphoribosyl transferase - Drugs In Development, 2022'; Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Speak directly to the analyst to clarify any post sales queries you may have.
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
The report 'Nicotinamide Phosphoribosyl transferase - Drugs In Development, 2022' outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System, Gastrointestinal, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Pulmonary Radiation Toxicity, Acute Lung Injury, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Depression, Diffuse Large B-Cell Lymphoma, Ewing Sarcoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Leukemia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
- The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
- AbbVie Inc
- Aqualung Therapeutics Corp
- Aurigene Discovery Technologies Ltd
- Calico Life Sciences LLC
- Eli Lilly and Co
- Genentech USA Inc
- Karyopharm Therapeutics Inc
- OncoTartis Inc
- Remedy Plan Inc
- Tianjin Hemay Pharmaceutical Co Ltd
- Valo Health LLC
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
- ALT-200 - Drug Profile
- Product Description
- Mechanism Of Action
- AU-4869 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- enamptcumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GNE-617 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hemay-088 - Drug Profile
- Product Description
- Mechanism Of Action
- KPT-9274 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LSN-3154567 - Drug Profile
- Product Description
- Mechanism Of Action
- OPL-0021 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OT-82 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- P7-C3A20 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RP-216 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- STF-118804 - Drug Profile
- Product Description
- Mechanism Of Action
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
- Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
- Featured News & Press Releases
- Apr 04, 2022: Aqualung Therapeutic's ALT-100 monoclonal antibody cited as a novel therapeutic for lung fibrosis
- Feb 01, 2022: Aqualung Therapeutic’s ALT-100 antibody significantly reduces ARDS severity in both rat and porcine (large animal) preclinical models
- Jan 25, 2022: Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
- Dec 07, 2021: CEO & Founder of Aqualung Therapeutics Joe G.N. Garcia MD to present corporate update at the Annual Biotech Showcase in San Francisco
- Aug 23, 2021: Aqualung Therapeutics selected to present at the Phoenix 2021 Venture Madness Competition on October 6-7th
- Jun 15, 2021: Aqualung Therapeutics plans A phase 0 ARDS trial for eNAMPT monoclonal antibody (Alt-100 mAb) following Type B FDA meeting
- Apr 05, 2021: Antengene announces NMPA approval of IND application for ATG-019 in patients with advanced solid tumors or non-Hodgkin's lymphoma
- Feb 11, 2021: eNAMPT, the inflammation-regulatory protein specifically targeted by aqualung therapeutic’s monoclonal antibody ALT-100, is now tightly linked to outcomes in COVID-19 infected patients
- Dec 02, 2020: Aqualung Therapeutics publication supports eNAMPT as both biomarker & therapeutic target in prostate cancer; prostate cancer KOL new addition to scientific advisory board
- Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury
- Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury
- May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill
- Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma
- Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)
- Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AbbVie Inc, 2022
- Pipeline by Aqualung Therapeutics Corp, 2022
- Pipeline by Aurigene Discovery Technologies Ltd, 2022
- Pipeline by Calico Life Sciences LLC, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Genentech USA Inc, 2022
- Pipeline by Karyopharm Therapeutics Inc, 2022
- Pipeline by OncoTartis Inc, 2022
- Pipeline by Remedy Plan Inc, 2022
- Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
- Pipeline by Valo Health LLC, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Aqualung Therapeutics Corp
- Aurigene Discovery Technologies Ltd
- Calico Life Sciences LLC
- Eli Lilly and Co
- Genentech USA Inc
- Karyopharm Therapeutics Inc
- OncoTartis Inc
- Remedy Plan Inc
- Tianjin Hemay Pharmaceutical Co Ltd
- Valo Health LLC
